Skip to content

Design Therapeutics, Inc. DSGN Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$535K-76.5%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$4.11M+77.9%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$1.18M+23.6%
Septerna, Inc. logo
Septerna, Inc.SEPN
$755K-21.8%
PVL
Palvella TherapeuticsPVLA

Other financials

Income statement

See full
Revenue-
Operating income-$19.7M+3.5%
Net income-$17.6M+0.4%
EPS (diluted)-$0.29+6.5%

Balance sheet

See full
Cash & equivalents$12.8M-6.6%
Total debt$2.7M+27.7%
Total equity$218.1M-4.3%
Total assets$230.4M-3.0%

Cash flow

See full
Operating cash flow-$16.4M+2.1%
CapEx--100%
Free cash flow-$16.4M+2.6%

Valuation

See full
Market cap$860.66M+305%
Enterprise value$850.62M+324%

Profitability

See full
Operating margin-3,685.8%
Net margin-3,663.7%

Returns & leverage

See full
Return on equity-31.3%+19.5pp
Debt / equity0.0×
Current ratio22.3×-6.1×

Where this comes from

Reported directly by Design Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Design Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Design Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
Design Therapeutics, Inc. (DSGN) reported accretion (amortization) of discounts and premiums, investments of $147K in Q1 2026.
How has Design Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
Design Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 86.1% year-over-year, from $1.06M to $147K.
What is the long-term trend for Design Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
Over 3 years (2022 to 2025), Design Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 32.6% compound annual growth rate (CAGR), from $1.4M to $3.25M.
What does accretion (amortization) of discounts and premiums, investments mean?
This metric represents the non-cash adjustment to net income resulting from the amortization of premiums or the accretion of discounts on debt or investment securities held by the company. It reflects the gradual adjustment of the carrying value of these assets toward their face value over time. Investors monitor this to understand how non-cash interest-related adjustments impact the company's reported operating cash flow.